Kane Biotech (KNE) Stock Statistics & Valuation Metrics

Kane Biotech has a market cap or net worth of C$7.46M. The enterprise value is C$9.05M.

Kane Biotech has 165,771,560 shares outstanding. The number of shares has decreased by -2.65% in one year.

Kane Biotech’s return on equity (ROE) is 1.86 and return on invested capital (ROIC) is -581.95%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Kane Biotech had revenue of 2.08M and earned -3.02M in profits. Earnings per share was -0.02.

In the last 12 months, operating cash flow was -4.23M and capital expenditures -91.06K, giving a free cash flow of -4.32M billion.

Kane Biotech pays an annual dividend of ―, resulting in a dividend yield of ―

Kane Biotech upcoming earnings date is Aug 28, 2025, TBA (Confirmed).

Kane Biotech as a current ratio of 0.43, with Debt / Equity ratio of -183.35%

In the past 12 months, Kane Biotech has paid -1.31M in taxes.

Kane Biotech EV to EBITDA ratio is -4.46, with an EV/FCF ratio of -4.00.

Kane Biotech has C$493.58K in cash and marketable securities with C$2.08M in debt, giving a net cash position of C$1.59M billion.

Gross margin is 33.21%, with operating margin of -215.96%, and net profit margin of -145.35%.

The average price target for Kane Biotech is ―, which is 11.43% higher than the current price. The consensus rating is Hold